DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

No life sciences company, not even the largest multinational, has all the answers needed to successfully translate a discovery into a tangible medicine. For early stage biotechs and emerging pharma companies working at the forefront of innovation and technology, the need for data and insights to drive strategic planning and ensure future success is particularly acute. At DRG, we understand that biotechs often have to do far more with fewer resources than their larger competitors. Our world class data sets, on-demand intelligence and reports are here to support biotechs with bespoke solutions that empower strategic decision-making and drive innovation forward. Whether planning your clinical or commercial strategy, our insights and solutions, backed by our robust data, provide the answers you need throughout the development pathway.

How can we support you?
Fundraising proposal due diligence

Investment decision support

Partnership & commercial strategies

Indication selection tactics

Growth & expansion

Product & proposal strategy

People and partnerships

"DRG has become the standard resource center for our company, whether to get quickly onboarded to the market landscape or using the epidemiology dashboards for our forecasts. The platform holds an abundance of information that is frequently updated and easily accessible. The high-quality information is also paired with fast and pleasant service from DRG representatives, leaving no gaps in our knowledge. The partnership is unbeatable in all aspects and comes highly recommended for all companies of any size."

Global business analyst

Biotech company

On-demand and bespoke intelligence at your finger tips

On-demand market assessment reports

On-demand market assessment reports

  • Disease landscape and forecasting
  • Epidemiology
  • Current treatment landscape
  • Treatment algorithms
  • Unmet need
  • Access and reimbursement
  • Biosimilars
  • China in-depth

Learn More

Data

Data

  • Claims
  • Electronic health records
  • Purchase order data
  • Encounter-level hospital device usage data
  • Social intelligence
  • Epidemiology

Learn More

Fundraising due diligence
Fundraising is arguably the most crucial task your company will undertake right through the development pathway. We specialize in helping companies not only with due diligence and fundraising business case dossiers but also ensuring your proposal will attract the right investors and stand out from the crowd. Venture capitalists are increasingly inundated with proposals for innovative programs. Let us help you accurately assess market opportunity and return on investment to ensure your proposal is turning heads with the prospective investors best suited to your offerings. Book a discovery call with an expert to learn more.

Related insights

...

Video

Successful fundraising

View now

...

On-demand Intelligence

Disease landscape and forecast reports

View now

...

Video

Biotech investment remains robust

View now

Indication selection tactics
For early stage biotechs, it is vitally important to effectively evaluate all indication options. At DRG, we have the insight and expertise to assess which indications will get you the most traction in terms of uptake, return on investment and patient health outcomes. While many companies today are pursuing orphan indications due to their advantageous development timeline, developers need to consider the long term strategy beyond initial indication. Let us help you determine your indication strategy and guarantee that your assets bring you and your investors the best long-term returns. Book a discovery call with an expert to learn more.

Related insights

...

Video

Creating an accurate picture of your asset’s commercial options

View now

...

On-demand Intelligence

Unmet need reports

View now

...

Case Studies

Sizing the drug treatable population for a rare disease

View now

Investment decision support
When making go/no-go decisions, at each stage of the development pathway, it is important to not only have a baseline assessment of your asset’s value and the risks involved but also what other strategic alternatives exist. Our on-demand intelligence, paired with the analytical rigor of our experts, will give you the insights you need to consider all options with confidence and inform more qualified decision-making. Book a discovery call with an expert to learn more.

Related insights

...

Video

Using epidemiology to assess ROI for a new molecule

View now

...

Case Study

Patient Segmentation Analysis for Value Demonstration

View now

...

On-demand Intelligence

Market sizing and forecasting

View now

Growth & expansion strategies
We support biotech companies with corporate and geographic expansion. Whether you are evaluating differing market opportunities or assessing how to build critical mass to become an attractive and sound investment prospect, DRG can help you paint an accurate picture based on robust data and decision science. Book a discovery call with an expert to learn more.

Related insights

...

Case Study

Orphan Drug Commercialisation in Europe)

View now

...

Video

Key commercial factors to consider during program development to forecast share of voice

View now

...

On-demand Intelligence

China in-depth reports

View now

Product & portfolio strategy
As your company and pipeline grows, you’ll need to be strategic about how you manage opportunities within your portfolio. Many early stage companies are making the transition to becoming commercial concerns. Is this the right step for you and are your assets correctly positioned to help you achieve this? DRG can help you weigh up the trade-offs of keeping assets in-house or partnering them out. Book a discovery call with an expert to learn more.

Related insights

...

Video

Transforming the treatment of cancer with oncolytic viruses

View now

...

Video

Inhouse commercialisation options (Seth Lederman)

View now

...

On-demand Intelligence

Global market access solutions

View now

Partnership & commercialisation strategies
As an emerging biotech with a small asset portfolio, it is important to make your assets go the extra mile. This often needs to be done with far less budget and manpower than your larger competitors have at their disposal. It is critical that you create an accurate picture of all the options for your asset in order to determine with confidence the most commercially-viable direction. At DRG, we work with small companies to accurately assess the value, risk drivers and market level threats of differing in-house and out-license commercialization options. Whether you are looking to transform your company into a commercial concern or looking for a mutually beneficial partnership, let our decision scientists and on-demand intelligence help you weigh up all the options. We’ve found the most interesting partnership discussions often begin when a company thinks they’ve reached the end of the road with an asset. Book a discovery call with an expert to learn more.

Related insights

...

Case Study

Integrated Patient Journey: How to optimize engagement for a commercial launch

View now

...

Video

Key commercial factors to consider during program development to forecast share of voice

View now

...

Video

Early planning key to successful access and product launch

View now

Our data repository underpins all of our solutions

Accurate sizing and forecasting enabled by diverse data sources and therapeutic and data experts


Claims

  • 26 billion claims
  • Visibility into 300+ million patients total
  • 220+ million patients captured annually
  • 2+ million healthcare providers
  • 98% of 750 U.S. payers, real-time updates
  • Hospitals, physician offices, ASCs, pharmacies, long-term care, nursing facilities

Health plan formulary & lives

  • 4,500+ formularies & restrictions data from 781 US payers (>90%)
  • 100% of US population enrollment data by coverage type
  • Hospital formulary data from 240 IDNs

Electronic health records

  • Visibility into 100+ million patients (over 3 years)
  • Diagnoses, diagnostic tests, assessments, vaccines, vitals, Rx

Social data

  • Anonymized social conversation data from public social platforms, online communities and message boards

Epidemiology

  • Coverage of 220+ diseases, vaccines and tumor biomarkers across up to 171 countries

Healthcare provider affiliation directory

  • 6.5+ million affiliations
  • Affiliations among 3,200 hospital systems and 2+ million HCPs

Meet some of our experts

"I have spent many years working in the business intelligence sector and one thing that separates DRG from our competitors is our desire to help clients. This translates into excellent post sale service from dedicated account managers, client service partners and the experts behind the information. We are here to help you, answer your questions and help you help your patients"

Owais Baig

Director of Business Development

Decision Resources Group

"Our team of dedicated experts are committed to providing deep therapeutic expertise within oncology and this is what sets us apart. In such a dynamic landscape, providing clients with actionable insights to meet their market research and market sizing needs is our first priority. Our comprehensive market intelligence helps clients identify opportunities and optimize long-term disease strategy. We work hand in hand with our Biotech clients helping them keep pace with shifting market dynamics in this rapidly evolving space. One thing our clients appreciate is that we are there to help answer their questions whenever they need us."

Sorcha Cassidy

Associate Director of Oncology

Decision Resources Group